drugset / Trial / NCT00159419
Bisphosphonate Therapy for Osteogenesis Imperfecta
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is designed to evaluate the efficacy and safety of "Bisphosphonate Therapy for Osteogenesis Imperfecta (OI)." We, the researchers at Indiana University School of Medicine, are characterizing the changes effected by oral bisphosphonate therapy and comparing them to a regimen of intravenous bisphosphonate therapy in a group of children with OI and also in children with other disorders that result in low bone mass and fractures.
Timeline
- Start
- 1999-08
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alendronic Acid | Small molecule | 1 mg/kg | Oral |
| Comparator | Pamidronate | Small molecule | 3 mg/kg | Intravenous |